Araujo-Castro, M, Biagetti, B, Menéndez, E, Novoa-Testa, I, Cordido, F, Berrocal, VR, Pascual-Corrales, E, Guerrero-Pérez, F, Vicente, A, García-Centeno, R, Gonzalez, L, Garcia, MDO, Echarri, AI, Rodríguez, MDM, Novo-Rodríguez, C, Calatayud, M, Villar-Taibo, R, Bernabéu, I, Alvarez-Escola, C, Jimenez, CT, Abellan-Galiana, P, Venegas, E, González-Molero, I, Iglesias, P, Blanco, C, De Lara, FVO, Novoa, MPD, Torres, ELM, Hanzu, F, Lamas, C, Rodriguez, SA, Aulinas, A, Recio, JM, Aviles-Pérez, MD, Núñez, MAS, Camara, R, Fano, MP, Fajardo, C, Cardoso, L, Marques, P, Martínez-Sàez, E, Ruz-Caracuel, I, Marazuela, M, Puig-Domingo, M. Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas. Endocrine Connections. 2025; 14(7)DOI:10.1530/EC-25-0103. PMID:40590355. IF:2.800(Q3/6D).

Villamarín , M, Fernández-Hidalgo, N, Escolà-Vergé, L. Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre-a counterpoint. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2025; 80(7)DOI:10.1093/jac/dkaf164. PMID:40396694. IF:3.600(Q2/3D).

Mosnaim, GS, Price, D, Côté, A, Plaza, V, Xia, CM, Awad, H, Kwah, J. DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE AND ASTHMA CONTROL IN PATIENTS WITH AND WITHOUT COEXISTING TYPE 2 CONDITIONS: RESULTS FROM THE RAPID STUDY. VALUE IN HEALTH. 2025; 28(6)DOI:. PMID:. IF:6.000(Q1/1D).

Ryan, P, Blanco, JL, Masia, M, Garcia-Fraile, L, Crusells, MJ, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Esteban, H, Gil, P, de Miguel, M, Alejos, B, Martínez, E. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025; 12(7)DOI:10.1016/S2352-3018(25)00105-5. PMID:40489982. IF:13.000(Q1/1D).